TP53 and breast cancer: (33) showed that patients with non-lymphocyte-dominant early-stage breast cancer with PIK3CA-only mutations had a favourable DFI, those with TP53-only mutations had a worse DFI and those with PIK3CA-TP53 co-mutations had the worst DFI.